Last reviewed · How we verify
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitor | Tyrosine kinase inhibitor | phase 3 | Tyrosine kinase inhibitor | Oncology |
Therapeutic area mix
- Oncology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akeso · 1 shared drug class
- Angion Biomedica Corp · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
- Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
- Centre Leon Berard · 1 shared drug class
- Chang-Ming Huang, Prof. · 1 shared drug class
- AB Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest:
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest pipeline updates — RSS
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest pipeline updates — Atom
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-f-r-klinische-krebsforschung-ikf-gmbh-at-krankenhaus-nordwest. Accessed 2026-05-17.